|
|
Purpose : To determine whether the prophylactic treatment with recombinant human
erythropoietin(rHuEPO) for the anemia of prematurity would reduce the need for blood
transfusions.
Methods : We randomly assigned 17 premature infants to therHuEPO group and the
control group. For the rHuEPO group (n=9, birth weight=1210¡¾156 g, gestational
age=31.7¡¾1.9wk), rHuEPO (400U/kg) was given three times a week for 4 weeks, plus
iron (8 mg/kg/day) and vitamin... |
